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Purpose: We applied Multi-Criteria Decision
Analysis (MCDA) methods in a structured
benefiterisk assessment of cladribine and newer
approved disease-modifying drugs (DMDs) for
patients with relapsing-remitting multiple sclerosis
(RRMS).
Methods: Decision conferencing with clinical
neurologists as decision makers was used to create an
MCDA model that incorporated available evidence
on DMDs for RRMS and clinical judgments about
the relevance of the evidence. Benefiterisk
assessments were conducted for DMDs in both
patients with RRMS and patients with RRMS with
high disease activity (HDA; defined as 2 relapses in
the previous year). Treatment options included
cladribine and recently approved DMDs available in
European Union countries at the time of assessment
(December 2015): alemtuzumab, dimethyl fumarate,
fingolimod, natalizumab, and teriflunomide. To
account for the relative importance of DMD effects,
scores for the MCDA model were weighted to ensure
that the most clinically important attributes carried
more weight in the final benefiterisk calculation. The
neurologists weighted different efficacy and safety
profile attributes without any reference to individualFebruary 2019DMDs to disassociate the assessment of weights with
any specific DMD. The neurologists did not do direct
comparisons between DMDs.
Findings: The highest overall weighted preference
value for the RRMS model was for dimethyl
fumarate (63) followed closely by cladribine (62). For
patients with RRMS and HDA, cladribine had the
highest overall weighted preference value (76),
followed by alemtuzumab (62) and natalizumab (61).
The benefiterisk balance of cladribine in patients
with RRMS and specifically patients with RRMS
who exhibited HDA characterized by high relapse
activity (2 relapses in the previous year) was more
favorable than the other DMDs included in the model.
Implications: The balance of high efficacy and the
safety profile makes cladribine an important
treatment option to consider, both in patients with
RRMS and patients with HDA. Regular, single-
country meetings could be organized to explore how
differences in cultural values (scores and weights) and249
Clinical Therapeuticsupdated input data might affect the usefulness of
MCDA in different, real-world, dynamic clinical
settings. (Clin Ther. 2019;41:249e260) © 2019 The
Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: cladribine, Multi-criteria Decision
Analysis, multiple sclerosis, relapsing-remitting, risk
assessment.* Trademark: MAVENCLAD (Merck KGaA, Darmstadt,
Germany).INTRODUCTION
Relapsing-remittingmultiple sclerosis (RRMS) is themain
phenotypeofmultiple sclerosis (MS).1,2 Prognostic factors
such as relapse rates3 and/or magnetic resonance imaging
(MRI) activity4 in patients with RRMS have been
associated with greater risk of disability progression in
the future. Increased availability of new treatment
options for RRMS over recent years has helped to
reduce relapses and new lesions, but worsening
disability is still an issue for many patients with MS,
regardless of treatment.5 Balancing efficacy versus the
risks associated with therapy is essential to the selection
of a treatment option for every patient with RRMS and
particularly for those patients at increased risk of
relapses and disability progression.6,7
A traditional view of MS therapy is that, although
higher efficacy treatments should be considered for
patients at higher risk, these therapies are associated
with additional safety profile concerns in some
patients.7 Basic understanding of the efficacy and
safety profiles of available disease-modifying drugs
(DMDs) does not provide a complete appreciation of
their benefiterisk balance. The experienced clinical
judgment of a treating neurologist about the clinical
relevance of the underlying favorable and
unfavorable effects of treatment options is required,
as well as the relative trade-off between the two, for
which it would be important to consider the patient's
view when deciding on a treatment plan.
Recommendations from the BenefiteRisk Project at
the European Medicines Agency (EMA)8,9 and from
the Pharmacoepidemiological Research on Outcomes
of Therapeutics by a European ConsorTium
(PROTECT) project of the European Commission's
Innovative Medicines Agency10 suggest that multi-
criteria decision analysis (MCDA) within a structured
benefiterisk assessment process could clarify and250facilitate communication about drug decision making.
In the work described here, we tested these
recommendations by applying them to a benefiterisk
assessment of cladribine (MAVENCLAD*) and 5 other
newer approved DMDs for treatment of both RRMS
and patients with high disease activity (HDA). To do
this, we applied the group workshop approach of
decision conferencing, guided by the EMA/PROTECT
framework to create an MCDA model that
incorporated both the available evidence for the DMDs
and clinical judgments from neurologists about the
relevance of that evidence.9,10METHODS
Oneof the authors (L. Phillips) facilitated the construction
of an initial MCDAmodel at a 2-day decision conference
in October 2015 with Merck KGaA staff providing
support to gather evidence from public domain sources.
A 1-day decision conference in December 2015,
attended by the Merck staff and 5 independent
European neurologists (authors P. Vermersch, V.
Martinelli, C. Pfleger, P. Rieckmann, and L. Alonso-
Magdalena) completed the model and confirmed its
validity. The steps in creating, exploring, and finalizing
the MCDA model are detailed in Supplemental Section
1 (in the online version at doi:10.1016/
j.clinthera.2018.12.015). Here, we briefly describe those
stages, the first of which, establishing the decision
context, was described in the Introduction above.
Alternatives
Medicinal products evaluated included cladribine
(under regulatory consideration at the time of the
assessment) and newer approved DMDs available at
the time of the assessment: alemtuzumab, dimethyl
fumarate, fingolimod, natalizumab, and teriflunomide.
Criteria
Seven favorable and 4 unfavorable effects criteria
developed at the October decision conference were
introduced at the December 2015 meeting to the
panel of neurologists, who discussed and agreed on
all 7 favorable effects and extended the 4 original
unfavorable effects to 11, the result of a discussion
that considered study end points, posology, andVolume 41 Number 2
y Hiview3 software, originally developed at the London
School of Economics and Political Science and now at
Catalyze Ltd, www.catalyze.co.uk, performed the con-
version after the ranges were established.
P. Vermersch et al.established or potential risks associated with the
DMDs. Neurologists decided to be overinclusive in
the number of criteria included in the final model. All
criteria were organized as a hierarchical effects tree.
Neurologists agreed definitions of the effects
criteria, recognizing that some flexibility was required
to accommodate inconsistencies in the literature. For
example, in a population of patients with RRMS
exhibiting HDA, the available information reported
that for most agents, data for patients having
experienced 2 relapses in the previous year were
available most consistently as a definition of HDA.
When data for this definition of HDA were not
available, but similar definitions of HDA were used
(eg, patients with 2 relapses in the previous year
plus at least 1 T1 gadolinium-enhanced [Gd+] lesion),
this alternative definition was used (see Supplemental
Section 2 for more details). It was also recognized
that relevant absolute reductions would be the most
informative data to characterize favorable effects.
However, it was not possible to obtain data
consistently for all of the DMDs. Therefore, relative
risk data were used for relapse rate, number of T1
Gd+ and T2 lesions, and time to 3- and 6-month
confirmed Expanded Disability Status Scale (EDSS)
progression in the model reported. Similarly, the
model used the percentage of patients who
experienced grade 4 lymphopenia, because data for
other grades were not reported for all of the DMDs.
Scoring
Before the decision conference, a hierarchical search
strategy obtained treatment effect data for the DMDs
by identifying relevant studies in the following order: (1)
European Union regulatory approval documents, (2) US
regulatory approval documents, (3) reports from post-
marketing surveillance, and (4) peer-reviewed
publications (pivotal trials; secondary publications).
Details of data and sources used in this model, including
assumptions, are given in Supplemental Section 2. For
both favorable and unfavorable effects, if the relevant
data were not found in the first data source, then the
second data source was searched and so on down the
hierarchy until relevant data were identified and the
search was stopped. Only 1 set of data was reported for
each effect for each DMD. Only trials in which the
DMD was given as monotherapy were chosen, and the
highest values for favorable effects attained in any trials
were included in the model (ie, the highest efficacyFebruary 2019result). For alemtuzumab, in which the clinical program
did not include placebo as a comparator, arbitrary high
values were assigned by the neurology experts on MRI
and clinical efficacy measures. Data on unfavorable
effects selected for inclusion in the model were based on
the important identified and potential risks associated
with the DMDs to be assessed. Generally, data were
captured at the MedDRA System Organ Class level
because the terminology across the different sources
varied. For the most part data were taken from 2-year
studies. Further refinement of the data continued
throughout the 2 decision conferences, with data from a
few new sources added after the meetings. Definitions of
the criteria and all input data were summarized in an
effects table (Table 1).
Most of the metrics in the effects table (Table 1) were
expressed as percentage reductions for the favorable
effects and incidence, expressed as percentages, for the
unfavorable effects. However, 4 effects were expressed
differently: (1) rankings based on ease of use; criteria
included oral versus intravenous administration, the
number of doses required–few or many, whether
monitoring is required during administration, and
whether co-administration of other drugs is required;
(2) durability of treatment effect, expressed as number
of months of remaining efficacy after stopping the
drug to reflect the acceptable interval of time (per
neurologists) to wait after interrupting a therapy to
switch to another without risking the appearance of
new relapses; (3) malignancy, expressed as number of
new cases per 100 patient-years; and (4) progressive
multifocal leukoencephalopathy (PML), expressed as
number of cases per 1000 patients.
MCDA deals with such differences in metric types
by converting all input data to a common metric of
preference value in a 2-step process. In the first step
the neurologists established a preference scale for
each criterion, with low and high values, including all
the input data in the effects table (Table 1), assigned
preference values of 0 and 100, respectively. In the
second step, the performance metrics for all drugs on
each scale were converted linearly to preference
scores by using Hiview3 software,y which preserved251
Table 1. Effects Table of input data for the RRMS population and the HDA subset (data shown in parentheses).
The low and high figures establish the range of data for which swing weights are assessed. Final nor-
malised weights are shown for the RRMS and HDA models. See also Supplementary section 2 for details
and reference sources.
Liver functions
Percentage of patients 
experiencing elevated
liver enzymes
% 20 0 2.5 2.4 1.5 0.0 10.1 6.0 0.0 15.0
Malignancy Number of new cases per 100 patient-years No/100 0.45 0.20 4.0 3.9 0.370 0.320 0.400 0.375 0.370 0.200
Autoimmune 
disease
Percentage of patients with 
any autoimmune
disease
% 50 0 6.0 5.9 2.0 0.0 0.0 0.0 47.0 0.0
Lymphopenia
Percentage of patients 
experiencing lymphopenia 
Grade 4
% 55 0 6.5 6.4 0.7 0.0 18.0 0.13 52.1 0.0
AV block
Percentage of patients with 
first degree AV
block
% 5 0 2.0 2.0 0.0 0.0 4.7 0.0 0.0 0.0
Bradycardia Percentage of patients with bradycardia % 4 0 1.5 1.5 0.2 0.0 4.1 0.0 0.3 0.0
Serious 
infections
Percentage of patients with 
any serious
infection
% 3 1.5 7.0 6.8 2.5 2.4 1.6 2.0 2.7 2.2
Herpetic 
infections
Percentage of herpetic 
infections % 16 0 5.0 4.9 7.9 8.0 9.0 0.0 15.7 0.5
PML Number of cases of PML per 1,000 patients No/1000 2 0 10.1 9.8 0.000 2.100 0.104 0.029 0.000 0.000
*(1) oral vs iv, (2) few or many doses, (3) monitoring during administration (Y or N) and (4) Co-administration of other drugs (Y or N).
AR=adverse reaction; AV=atrioventricular; EDSS=expanded disability status scale; Gd+=gadolinium enhanced; GI=gastrointestinal; HDA=high disease activity; 
iv=intravenous; PML=progressive multifocal leukoencephalopathy.
Clinical Therapeutics
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approach was taken as an appropriate approximation
for the criteria under consideration where an effect is
measured by proportions of patients, to ensure all
patients are treated equally. The number of cases of
atrioventricular block, bradycardia, and PML are so
small they would all appear on a linear portion of
the value function. Thus, for the relative reduction
percentages of the favorable effects, a larger input
metric received a higher preference score, while for
the unfavorable effects, a higher percentage or
incidence was assigned a lower preference score.
Consequently, higher numbers for unfavorable effects
represent better safety. The resulting preference
values therefore represent the strength of preference
for the performance of each of the 6 drugs on each
of the 18 effect scales.
Weighting the Effects Criteria
The differences in preference between 0 and 100 on
some of the scales are clearly more clinically relevant
than on others, so in MCDA the scales are weighted
to ensure the comparability of a unit of preference
from one scale to the next. This enables weighted
preference values to be summed to give an overall
benefitesafety figure for each DMD. The process of
doing this is called swing weighting, because it
requires the swing in clinical desirability from the 0-
to-100 point on one scale to be compared with that
on another. This process of weighting requires
consideration of how large the range is on a given
criterion, and an assessment of how clinically
important that range is. The process of weighting
was helped by Hiview's projected vertical graphic
scales indicating only the worst and best values of the
input data. These displays enabled neurologists to
judge the added clinical value of moving from the
worst to the best scale points on one criterion
compared with another, a paired-comparison
approach that minimizes the cognitive task of
considering too many criteria at once.
The neurologists weighted different efficacy and
safety profile attributes without any reference to
individual DMDs to disassociate the assessment of
weights with any specific DMD. The neurologists did
not do direct comparisons between DMDs.
The objective element of a weight is given by the size
of the metric's range; that difference is interpreted
subjectively and expressed as a number. DifferencesFebruary 2019between ranges are compared from one criterion to
the next, always assigning an arbitrary weight of 100
to the largest range within a set of criteria and then
comparing the weighted criteria across the sets.
In a hierarchical model such as the present model,
the weighting proceeds from comparing criteria under
a grouping to comparisons between groups, through
to the final comparison that assesses the swing
between the most favorably weighted criterion and
the most unfavorably weighted criterion. These last
swing weights represent the trade-off between the
most beneficial favorable effect and the unfavorable
effect associated with most risk.
Generating Results for the Model
With scoring and weighting completed and all data
and weights entered into the computer model, the
Hiview3 software calculated the weighted average of
the preference scores on the 18 criteria and summed
the scores to give a single overall weighted preference
value for each drug. In addition, the benefiterisk
balance of each DMD was compared with that for
cladribine. That process followed established
priorities for assessing the DMDs and reflected the
contributions that individual effects make to the
overall weighted preference value for each.
Sensitivity Analyses
Two approaches were taken in sensitivity analyses.
First, the criterion weights between the favorable and
unfavorable effects were varied to explore the effects
of uncertainty and differences in judgments on the
final ordering of the drugs. Second, the effects of
different input data for some drugs on individual
criteria were varied (see Supplemental Section 3 for
more detail). These 2 types of analyses were
performed for both the RRMS model and the HDA
model.
RESULTS
The effects tree of Figure 1 shows the hierarchical
model. The effects table (Table 1) provides the names
and definitions of the criteria, the data metric, the
worst to best ranges of the data, the weights assessed
for the RRMS and HDA models, and the input data
for both models.
Figure 2 shows the overall weighted preference
values, which take into account available data for the
favorable and unfavorable effects, as well as253
Clinical Therapeuticsjudgments of the neurologists about the clinical
relevance of the effects for the RRMS and HDA
populations. Note that the bottom section of each
histogram indicates “safety” of the DMDs (higher
values represent better safety) and the top section
represents “benefits” (higher values represent more
benefit). The overall weighted preference values are
therefore a sum of the “safety” and “benefits” for
each DMD.
The highest overall weighted preference value for
the RRMS model was for dimethyl fumarate (63)
followed closely by cladribine (62). For patients with
HDA, cladribine had the highest overall weighted
preference value (76), followed by alemtuzumab (62)
and natalizumab (61). The effects with the largest
swing-weights were relative reduction in the time to
6-month confirmed EDSS progression over 2 years
and incidence of PML (number of cases per 1000
patients).
The neurologists found that the trade-off weight
between the most favorable and most unfavorable
effect to be the most difficult judgment, so the sum of
the benefits against the sum of the safety profile effects,
before making that trade-off assessment, was plotted
for each model (Figure 3). This revealed interesting
relationships among the DMDs; for example, that
cladribine and dimethyl fumarate were both judged to
be more beneficial and safer than fingolimod, whatever
the relative weights between benefits and safety. In the
RRMS model, the 4 DMDs that lie on the line from
alemtuzumab, judged to be the most beneficial, down
to dimethyl fumarate, judged to be the most safe
(ignoring teriflunomide, which is also safe but much
less beneficial), established a set of 4 drugs for which
more benefit means more risk. Cladribine appeared
slightly more beneficial and a little less safe than
dimethyl fumarate. Natalizumab appeared at about the
half-way point on the line, more beneficial than
cladribine but less safe.
For the HDA subgroup model, cladribine moved to
an upper-right position, between alemtuzumab and
dimethyl fumarate in the RRMS model to a position
that would favour the drug over all others over a wide
range of the trade-off weights between benefits and
safety. Only a modest increase in benefits would be
expected from alemtuzumab, compared with
cladribine, at a considerable decrease in safety.254Sensitivity Analyses
In the RRMS model, changing the weight on the
unfavorable effects node found that dimethyl
fumarate was the most preferred drug over a range
about 49 to 96. Below this, alemtuzumab was most
preferred; above this teriflunomide was most
preferred. Over a similar range, cladribine was
second to dimethyl fumarate. Cladribine became
most preferred with small-to-modest increases of the
weight on any of the individual criteria of 6-month
confirmed EDSS progression, ease of use, durability,
infections, and liver function. See Supplemental
Section 3 for details.
In the HDAmodel, cladribine was the most preferred
drug on unfavorable effects, over a range from 19 to 87.
Below this, alemtuzumab was most preferred; above
this, dimethyl fumarate was most preferred until high
weight when teriflunomide was most preferred.
Increasing or reducing weights of individual criteria
changed the most preferred DMD, depending on that
criteria (see Supplemental Section 3).
Changes in input data, for 3- and 6-month
confirmed EDSS progression and the incidence of
PML, grade 4 lymphopenia, and malignancy (see
Table 1 of Supplemental Section 3), found that
cladribine had a robust benefiterisk balance
compared with other DMDs. Despite the hypothetical
input data for favorable effects assigned to
comparators, cladribine retained its place in terms of
benefiterisk, as the most preferred agent for HDA
and its second position (after dimethyl fumarate) for
RRMS. With respect to unfavorable effects, the only
sensitivity analysis for which the relative preference
for cladribine compared with other DMDs was not
maintained was based on increased input data
(0.7%e52.1%) for the grade 4 lymphopenia
criterion. For the HDA model, cladribine remained
the most preferred option in all these sensitivity
analyses.
DISCUSSION
The results of the present model found that in the
context of HDA, cladribine had the most favorable
benefiterisk balance compared with the other DMDs
evaluated and was a close second to dimethyl
fumarate for the overall RRMS population (overall
weighted preference value for cladribine was 62Volume 41 Number 2
Fig. 1. The effects tree for comparing the 6 disease-modifying drugs (DMDs) in the Multi-Criteria Decision
Analysis (MCDA) model. (AR ¼ adverse reaction; AV ¼ atrioventricular; CVS ¼ cardiovascular safety;
EDSS ¼ Expanded Disability Status Scale; Gd+ ¼ gadolinium-enhanced; GI ¼ gastrointestinal;
PML ¼ progressive multifocal leukoencephalopathy; SAR ¼ serious adverse reaction.)
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Fig. 2. The overall weighted preference values for the 6 drugs (upper: relapsing-remittingmultiple sclerosis model;
lower: high disease activity model) shown in the Total row. Note that the bottom section of each histogram
indicates “safety” of the DMDs (higher values represent better safety) and the top section represents
“benefits” (higher values represent more benefit). The overall weighted preference values are therefore a
sumof the “safety” and “benefits” for eachDMD.Weights shown in the white field are the sums of the non-
normalised cumulative weights, and the normalised values are given in the right column.
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Fig. 3. The 6 drugs compared favorable effects
with unfavorable effects, which ignores
the relative weights between the 2 sets of
effects (upper: relapsing-remitting multi-
ple sclerosis model; lower: high disease
activity model).
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February 2019versus 63 for dimethyl fumarate). The work considered
the judgments of neurologists on the favorable and
unfavorable effects of the DMDs included in the
model, according to evidence available in December
2015. The outcome indicated that the balance of high
efficacy and the safety profile makes cladribine an
important treatment option to consider, both in
patients with RRMS and patients with HDA.
It is important to recognize that the overall purpose
of MCDA is to provide guidance on a specific problem,
based on the decisions of a defined group. It does not
set out to provide the right answer. MCDA methods
may help prescribers by informing more objective
decisions about the appropriate DMD to recommend
to an individual patient. In this MCDA model, the
judgments were made by neurologists with specific
expertise in the therapeutic profiles of DMDs and
who understood the importance of different aspects
of MS and its treatment, with an objective view of
the size of possible treatment effects. The
neurologists' preferences were relevant to the decision
problem, and a direct contribution from patients or
caregivers was not included in the MCDA.
Nevertheless, individual patient preferences and
lifestyle must also be considered carefully, discussed
fully, and included in overall treatment decisions to
encourage long-term adherence and to ensure that the
optimum balance of benefiterisk is most likely to be
positive in specific circumstances. Many other
approaches aimed at supporting patients in their
decisions about treatment options are often based on
assumptions or patient reports of preference only and
are therefore less systematic methods than
MCDA.11e16
Similarly, cost-effectiveness of treatments for MS is
an important consideration but was outside the scope
of the exercise reported here because cladribine
tablets were not commercially available at the time
the work was undertaken. However, a cost-
effectiveness analysis has recently been published,
reporting that cladribine is a cost-effective alternative
to alemtuzumab and natalizumab in the treatment of
HDA from the perspective of the National Health
Service in England.17
Over recent years the range of DMDs available for
MS has grown, with each drug having characteristic257
Clinical Therapeuticsefficacy and safety profiles. The favorable and
unfavorable effects identified for the present model
were selected to be inclusive and therefore cover the
most important features of all the DMDs included.
To achieve this meant that the present model had a
relatively large number of effects, particularly
unfavorable effects, which were needed to encompass
the known or potential risks associated with the
range of DMDs included.
Uncertainty because of imprecision of data was also
a problem in the present model which used relative risk
reductions for relapse rate, number of T1 Gd+ and T2
lesions, and time to 3- and 6-month confirmed EDSS
progression rather than absolute reductions because it
was not possible to obtain consistent data across all
the DMDs included. Clinical, MRI, and safety profile
data used for the effects table (Table 1) were
collected from different clinical studies conducted in
different patient populations, and definitions of HDA
in reported data were not identical for every DMD.
We also acknowledge that selecting the most
favorable set of data, rather than an alternative such
as the most conservative, a blended value, or
according to the quality of evidence, will influence
the results of the MCDA model. It should also be
noted that in clinical practice, the benefits and risks
of natalizumab for an individual patient in terms of
PML risk must also take account of John
Cunningham virus status.18,19 However, sensitivity
analyses in the present work did explore potential
disagreements and imprecision of the effects criteria.
More information about the methods used to identify
input data for the effects table (Table 1) and the basis
for sensitivity analyses is shown in Supplemental
Information Sections 2 and 3. For the present model,
input data in the effects table (Table 1) were the most
robust available at the time the exercise was
conducted, and changes in the input data for 3- and
6-month confirmed EDSS progression and the
incidence of PML and malignancy did not change the
relative preference for cladribine compared with
other DMDs.
Sensitivity analyses of the trade-off weights between
the favorable and unfavorable effects for the RRMS
model found that dimethyl fumarate and cladribine
remained in first- and second-place preference over a
wide range of weights, which may well accommodate
the preferences of many clinicians and patients. For258the HDA model, cladribine remains most preferred
because of its high scores for both benefits and
safety, so the trade-off is almost irrelevant to decision
making.
Finally, an important caveat of this model is the
limited number of neurologists who provided clinical
judgments based on available evidence. The
neurologists involved were representing their own
views and not those of any specific group or
organization's viewpoint when making decisions.
Caution is required when interpreting the data which
may not be representative of the wider, MS specialist
community. Reflecting this, the authors suggest that
regular, single-country meetings could be organized
to explore how differences in cultural values (scores
and weights) and updated input data might affect the
usefulness of MCDA in different, real-world,
dynamic clinical settings.
CONCLUSIONS
The MCDA model described in this report was
developed by using decisions from 5 independent
European neurologists, who weighted different
efficacy and safety profile attributes without any
reference to individual DMDs. The resulting model
suggests that the benefiterisk balance of cladribine,
in patients with RRMS and specifically patients with
RRMS who exhibit HDA characterized by high
relapse activity (2 relapses in the previous year),
was favorable compared with the other DMDs
included in the model.
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INFORMATION
Section 1
Steps in creating and exploring the MCDA model1Step Task
CONTEXT
1. Establish the decision context
 Review the current landscape of MS treatment options.
 Recognize the unmet medical need, severity and morbidity of
condition, affected population, patients' and physicians' concerns,
time frame for health outcomes.
ALTERNATIVES
2. Identify the options.
 Describe the comparators
CRITERIA
3. Identify and define the
criteria for assessing the
effects of each alternative.
Represent these in an Effects
Tree (Value Tree).
 Select the favourable effects (eg, endpoints, clinical outcomes,
durability, and ease of use).
 Select the unfavourable effects (eg, adverse events, serious adverse
events, infections, serious infections, major cardiac events,
malignancies, progressive multifocal leukoencephalopathy).
SCORING
4. Describe how the alternatives
perform for each of the
criteria and show how to
convert input data into
preference values (ie, assess
value functions).
 Gather available data. Present data summaries and confidence
intervals.
 Provide data summaries in an ‘Effects Table’ with alternatives in
columns and criteria in rows.
 Assess linear or non-linear value functions, usually direct (more
means better) for favourable effects, and inverse (more means
worse) for unfavourable effects.
WEIGHTING
5. Establish a measurement
scale for each criterion and
assess the relative importance
of the scales.
 Define each effect's measurement scale and its units (eg,
proportions, incidence) and determine upper and lower limits that
encompass a plausible range for the data. In most cases minimum
and maximum defined the range.
 Assess swing-weights to represent the clinical relevance of the swing
from lower to upper limit on each scale.
RESULTS
6. Calculate results and provide
graphical displays.
 Multiply preference values and criterion weights and sum the
products to obtain overall value (carried out by Hiview3 software).
 Construct preference-value bar graphs for favourable and
unfavourable effects, and for individual effects.
 Calculate difference displays for pairs of alternatives.
SENSITIVITY ANALYSES
7. Explore effects of uncertainty
on the benefit-risk balance.
 Vary individual weights over their entire range from 0 to 1.0; display
the overall results graphically.
 Change input data in order to check the impact of changing values,
which are important but are associated with a high level of
uncertainty.
 Examine the overall benefit-risk balance under possible future
scenarios by changing input data and criteria weights.







 Judge the relative importance and effect of the decision maker's risk
tolerance for this product (eg, unmet medical need, risk
management plan).
 Consider how this decision is consistent with similar past decisions,
might set a precedent, or make similar decisions in the future easier
or more difficult.
MCDA, Multi-criteria decision analysis.
Clinical TherapeuticsSection 2
Rationale for the favourable and unfavourable effects
of DMDs including in the MCDA models
This document describes the approach used to
identify source data and populate the effects table
used for the benefit-risk assessment of oral cladribine
compared with other disease modifying drugs
(DMDs) in both relapsing remitting multiple sclerosis
(RRMS) patients and those demonstrating high
disease activity (HDA).Identification of data and sources for each of the
favourable effects
Cladribine 3.5 mgk/kg
Annualized relapse rate (ARR) was the primary
endpoint in the Phase III CLARITY trial. For the
analysis, data for the cladribine 3.5 mg/kg dose
group from the CLARITY trial has been used.2 In the
CLARITY trial, the primary endpoint, ARR, was
met, with cladribine 3.5 mg/kg reducing ARR to 0.14
compared to an ARR of 0.33 in placebo patients,
showing a relative risk reduction of 58%.2 Standard
measures of disability progression are time to
sustained disability progression, measured by a 3-
month or 6-month confirmed change in expanded
disability status scale (EDSS) score. Both timepoints
for assessment of change in EDSS are widely accepted
as demonstrative of disability progression; and time
to 3-month sustained disability progression was
chosen as a study endpoint in the cladribine studies.
In the CLARITY trial cladribine 3.5 mg/kg led to a
lower risk of 3-month confirmed EDSS progression
(hazard ratio [HR] of 0.67, 95% confidence interval
[CI] of 0.48e0.93), a relative risk reduction of 33%.2260.e2An analysis of 6-month confirmed EDSS progression
in patients from CLARITY was included in the
combined summary of efficacy. In this analysis,
cladribine 3.5 mg/kg led to a relative risk reduction
of 6-month confirmed EDSS progression (HR of
0.53, 95% CI of 0.36e0.79), of 47% (data on file).
In the CLARITY study, there was strong suppression
of T1 Gd+ lesions (lease squares [LS] mean number
of lesions 0.12 for cladribine 3.5 mg/kg, and 0.91 for
placebo; a relative risk reduction of 86%) and active
T2 lesions (LS mean number of lesions 0.38 for
cladribine 3.5 mg/kg, and 1.43 for placebo; a relative
reduction of 73%).2
High disease activity subset
In the HDA group relevant to this analysis (patients
with 2 or more relapses in previous year, regardless of
previous treatment status), cladribine 3.5 mg/kg
reduced ARR to 0.16 compared to an ARR of 0.50
in placebo patients, showing a relative risk reduction
of 68%. Cladribine 3.5 mg/kg reduced the risk of 3-
month confirmed EDSS progression by 72% and
reduced the risk of 6-month confirmed EDSS
progression by 82% (data on file).Natalizumab 300mg
Natalizumab was evaluated in two randomized,
double-blind, placebo-controlled trials in patients
with MS. Both studies enrolled patients who
experienced at least one clinical relapse during the
prior year and had an EDSS score between 0 and
5.0. Study 1 (monotherapy study) enrolled patients
who had not received any IFN-b or glatiramer
acetate for at least the previous 6 months;
approximately 94% had never been treated with
these agents.3 Study 2 (add-on study) enrolledVolume 41 Number 2
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while on treatment with IFN-b-1a IM once-weekly
during the year prior to study entry; patients
continued to receive IFN-b-1a 30 mg IM once-weekly
during the study and were randomly assigned to
natalizumab or placebo.3 In Study 1, there was a
placebo-adjusted annualized relapse rate (ARR) of
68% and a 42% reduction in relative risk of
disability progression. In Study 2, there was a
placebo-adjusted ARR of 56% and a 24% reduction
in relative risk of disability progression. So, for the
effects table, the higher values from Study 1 were
used for the ARR (68%) and 3-month confirmed
EDSS risk reduction (42%).4 The sensitivity analysis
of progression of disability that was sustained for 24
weeks yielded a 54% risk reduction in the
natalizumab group (hazard ratio, 0.46; 95% CI, 0.33
to 0.64),4 so this value (54%) was used for the 6-
month confirmed EDSS risk reduction.
Natalizumab led to an 83% reduction in the
accumulation of new or enlarging hyperintense
lesions, as detected by T2-weighted MRI, over two
years (mean numbers of lesions, 1.9 with
natalizumab and 11.0 with placebo). There were
92% fewer lesions (as detected by gadolinium
enhanced MRI) in the natalizumab group than in the
placebo group at both one and two years.4
High disease activity subset
For the high disease activity subset (at least two
relapses in the previous year, or at least two relapses
in the previous year and at least 1 T1 Gd+ lesion),
data were taken from the Tysabri EPAR.5 ARR was
0.282 in the natalizumab group and 1.455 in the
placebo group, a reduction of 81%. A 3-month
confirmed EDSS HR of 0.47 (95% CI 0.24, 0.93) and
a 6-month confirmed EDSS HR of 0.36 (95% CI 0.17,
0.76) were reported, and the reduction in risk of 53%
and 64%, respectively were used in the effects table.
Fingolimod 0.5mg
Efficacy of fingolimod was demonstrated in two
studies that evaluated once daily doses of fingolimod
0.5 mg and 1.25 mg in patients with RRMS, one
placebo-controlled study and one active-controlled
study. Study 1 was a 2-year randomized, double-
blind, placebo-controlled study in patients with
RRMS who had not received any interferon-beta
(IFN-b) or glatiramer acetate for at least the previous
3 months and had not received any natalizumab forFebruary 2019at least the previous 6 months.6 In this study, the
ARR was significantly lower in patients treated with
fingolimod 0.5 mg (0.18) than in patients who
received placebo (0.40), a relative reduction of 54%
(entered in the effects table). Time to onset of 3-
month confirmed disability progression was
significantly delayed with fingolimod 0.5 mg
treatment compared to placebo (HR, 0.70, 95% CI
0.52, 0.96) and regarding disability progression that
was confirmed after 6 months, the risk was also
reduced with fingolimod 0.5 mg over the 24-month
study period (HR, 0.63, 95% CI 0.44, 0.90).
Therefore, the 3-month and 6-month EDSS risk
reductions were entered as 30% and 37%,
respectively.
The mean number of new or newly enlarging T2
lesions over 24 months was 2.5 in the fingolimod
0.5 mg group and 9.8 in the placebo group, a
reduction of 74%. The mean number of T1
Gd+ lesions at 24 months was 0.2 in the fingolimod
0.5 mg group and 1.1 in the placebo group, a
reduction of 82%.6
High disease activity subset
For the high disease activity subset (two or more
relapses in the previous year), data were taken from
the EPAR.7 The ARR rate ratio was 0.37 (95% CI
0.27, 0.51) so a relapse rate reduction of 63% was
entered in the effects table. The 3-month confirmed
EDSS risk reduction was 33% (HR of 0.67, 95% CI
0.40, 1.11). The same value was used for the 6-
month confirmed EDSS risk reduction in the effects
table because this analysis was not reported.
Alemtuzumab 12 mg
Efficacy of alemtuzumab in MS was established in
two open-label, rater-blinded, active-comparator
(IFN-b-1a) Phase III trials: one in treatment-
experienced RRMS patients (CARE MS II, also
known as CAMMS 324) and a second in treatment-
naive RRMS patients with early, active disease (ie, as
a first-line treatment) (CARE MS I, also known as
CAMMS 323). There are no placebo-controlled
studies of alemtuzumab. In both pivotal studies,
alemtuzumab was administered by intravenous
infusion once daily over a 5-day course, followed one
year later by intravenous infusion once daily over a
3-day course. The clinical outcome measures in both
studies were the ARR over 2 years and the time to
confirmed disability progression.8260.e3
Clinical TherapeuticsAlemtuzumab demonstrated a statistically
significant IFN-b-1a-adjusted effect on ARR
reduction in treatment-experienced RRMS patients
(49%)9 and in treatment-naïve RRMS patients
(55%).10 The 6-month confirmed EDSS risk
reduction was 42% in treatment-experienced RRMS
patients (Coles et al 2012) and 30% in treatment-
naïve RRMS patients (Cohen et al 2012). For the
purposes of the benefit-risk analysis the higher
relapse rate of 55% was chosen and arbitrarily
increased by 20% on the assumption that the effect
would have been greater relative to placebo.
Therefore, the ARR value entered into the effects
table for alemtuzumab for the RRMS analysis was
75%. Similarly, for 6-month confirmed EDSS risk
reduction the higher value was chosen (42%) and
arbitrarily increased by 20% to give a value of 62%
which was entered in the effects table. The same
value was used for the 3-month confirmed EDSS risk
reduction in the effects table because this analysis
was not reported.
In treatment refractory RRMS patients the
proportion of patients with new or enlarging T2-
hyperintense lesions at 24 months was 68% in the
IFN-b-1a group and 46% in the alemtuzumab
group.9 Corresponding data for treatment-naïve
RRMS patients were 58% and 48%, respectively.10
Similarly, the proportion of refractory RRMS
patients with gadolinium enhancing lesions at 24
months was 23% in the IFN-b-1a group and 9% in
the alemtuzumab group,9 while for naïve patients the
proportions were 19% and 7%, respectively.10 These
publications did not provide data on mean number
of active T2 lesions or mean number of T1
Gd+ lesions. This information was also not found in
the Lemtrada EPAR.11
For the purposes of the benefit-risk analysis it was
concluded that if alemtuzumab had been compared
with placebo, MRI efficacy would have been
extremely high. Consequently, arbitrary values of
87% and 92% reduction were included in the effects
table for T2 lesions and T1 Gd+lesions, respectively,
as a conservative approach.
High disease activity subset
In the CARE MS I (CAMMS 323) study the ARR
risk ratio for “patients with >2 relapses” was 0.53,
consistent with a 47% risk reduction and the risk
ratio for the “highly active population” was 0.49
consistent with a 51% risk reduction.11 Similarly, in260.e4the CARE MS II (CAMMS 324) study the ARR risk
ratio for “patients with >2 relapses” was 0.51,
consistent with a 49% risk reduction and the risk
ratio for the “highly active population” was 0.49
consistent with a 51% risk reduction.11 Since these
results were obtained in a trial against IFN-b-1a and
not against placebo, an arbitrary ‘premium’ was
assigned and a value of 71% ARR risk reduction was
entered in the effects table.
In the CARE MS I (CAMMS 323) study the 6-
month confirmed EDSS risk reduction for “patients
with >2 relapses” and for the “highly active
population” was 17% and 13%, respectively (risk
ratios of 0.83 and 0.87, respectively).11 Similarly, in
the CARE MS II (CAMMS 324) study the 6-month
confirmed EDSS risk reduction for “patients with >2
relapses” and for the “highly active population” was
23% and 51% respectively (risk ratios of 0.77 and
0.49, respectively).11 The of 20% was added to give
a value of 71%. This value was entered in the effects
table for both the 3-month confirmed EDSS risk
reduction and the 6-month confirmed EDSS risk
reduction.
As for the overall RRMS population, it was
concluded that had alemtuzumab been compared
with placebo, MRI efficacy would have been
extremely high and slightly higher in the HDA
population than the overall population.
Consequently, arbitrary values of 92% and 97%
reduction were included in the effects table for T2
lesions and T1 Gd+ lesions, respectively.
Dimethyl fumarate
Efficacy of dimethyl fumarate in MS was established
in two randomized, double-blind, placebo-controlled
studies in RRMS12,13; one of the studies also
included a glatiramer acetate reference arm. In each
study the primary endpoint was the proportion of
patients relapsed at 2 years. Additional endpoints at
2 years included the number of new or newly
enlarging T2 hyperintense lesions, number of new T1
hypointense lesions, number of Gd+ lesions, ARR,
and time to confirmed disability progression. In the
study that included the glatiramer acetate arm,
statistical significance against placebo was not
confirmed for either active treatment on the
secondary endpoint of sustained disability
progression but statistical significance against placebo
was confirmed for all other endpoints.14 In the otherVolume 41 Number 2
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confirmed for all endpoints.14 An improvement in
disability outcomes was statistically significant in a
pooled analysis of the entire Phase III program.15 As
the benefits of dimethyl fumarate were better in
Study 1 (also known as DEFINE and 109MS301)
than Study 2 (also known as CONFIRM and
109MS302), the data from Study 1 have been used in
the effects table.
In Study1 theARRat 2 yearswas 0.17 in the dimethyl
fumarate 240 mg bid group compared with 0.36 in the
placebo group, representing a relative reduction of
53%.13 The estimated proportion of patients with 3-
month confirmed EDSS was 16% in the dimethyl
fumarate 240 mg bid group and 27% in the placebo
group, a relative risk reduction of 38% (HR 0.62;
95% CI, 0.44 to 0.87). Data for the 6-month
confirmed EDSS were not included in the publication13
but are provided in Tecfidera EPAR.16 The HR is
given as 0.77 (95% CI, 0.52 to 1.14), a relative risk
reduction of 23%. In Study 1, as compared with
placebo, dimethyl fumarate 240 mg bid reduced the
number of new or enlarging hyperintense lesions on
T2-weighted images at 2 years by 85% and decreased
the mean number of T1 Gd+ lesions from 1.8 to 0.1, a
reduction of 94%.13 These values were used in the
effects table (for the RRMS analysis).
High disease activity subset
For the high disease activity subset (2 or more
relapses and at least 1 T1 Gd+ lesion), pooled data
from Study 1 and Study 2 were presented in the
Tecfidera EPAR.16 In this subset, the ARR at 2 years
was 0.23 in the dimethyl fumarate 240 mg bid group
compared with 0.58 in the placebo group,
representing a relative reduction of 60% (HR 0.40,
95% CI 0.22, 0.71). The 3-month confirmed EDSS
was 26% in the dimethyl fumarate 240 mg bid group
and 33% in the placebo group, a relative risk
reduction of 21%. The same value was used for the
6-month confirmed EDSS risk reduction in the effects
table because this analysis was not reported.
Teriflunomide
The efficacy of teriflunomide in patients with RRMS
was demonstrated in two similarly designed, Phase III,
randomized, double-blind, placebo-controlled,
parallel-group studies (TOWER and TEMSO) and
one Phase III, randomized, single-blind, parallel-
group, study comparing teriflunomide with IFN-b-1a.February 2019In the two placebo-controlled studies, teriflunomide
significantly reduced the ARR and significantly
reduced the risk of sustained accumulation of
disability (at the licensed dose of 14 mg once daily).
Although both placebo-controlled studies showed a
relative risk reduction for the primary outcome of
ARR of >30%, the adjusted ARR in both the
placebo and active treatment groups was low in both
studies, so that the absolute risk reduction in ARR
was small (<0.2).17,18
In the TOWER study, teriflunomide 14 mg
significantly reduced the ARR (adjusted rates of 0.50
[95% CI 0.43, 0.58] for placebo versus 0.32 [95%
CI 0.27, 0.38] for teriflunomide 14 mg),
corresponding to relative rate reduction of 36%.19
Similar results were seen in the TEMSO study with a
relative rate reduction of 31%.20 For the purpose of
the benefit-risk analysis, the higher value from the
TOWER study was used.
In the TOWER study a 31.5% reduction in the risk
of sustained accumulation of disability was observed
with teriflunomide 14 mg compared with placebo.19
Similar results were seen in the TEMSO study with a
29.8% reduction.20 A value of 31% was used in the
benefit-risk analysis for 3-month confirmed EDSS.
In an integrated analysis of the TOWER and
TEMSO studies, the relative reduction in the 6-
month confirmed EDSS was 24% (HR 0.76 95% CI
0.57, 1.01).21
In the TEMSO study, patients in the teriflunomide
14 mg group had fewer T1 Gd+ lesions per scan than
those in the placebo group. Relative risk versus
placebo was 0.2 (95% CI 0.12, 0.32), indicating an
80% reduction.20
The effect of teriflunomide 14 mg on MRI activity
was also demonstrated in a Phase II, randomized,
double-blind, placebo-controlled clinical trial of
multiple sclerosis patients with relapses.22 MRI was to
be performed at baseline, 6 weeks, 12 weeks, 18
weeks, 24 weeks, 30 weeks, and 36 weeks after
treatment initiation. Secondary endpoints in this study
were based on MRI scans including, average number
of new T2 lesions per scan. The mean number of new
or newly enlarging T2 lesions was 1.52 in the placebo
group and 0.71 in the teriflunomide 14 mg group,
indicating a reduction of 53%.
High disease activity subset
In the TEMSO study a subgroup analysis of patients
with high disease activity (2 or more relapses and at260.e5
Clinical Therapeuticsleast 1 T1 Gd+ lesion at baseline; N ¼ 127) showed an
ARR relative reduction of 19% (RR 0.81, 95% CI
0.51, 1.28) and 3-month confirmed EDSS relative
reduction of 35% (HR 0.65, 95% CI 0.26, 1.59).21
The same value (35%) was used for the 6-month
confirmed EDSS risk reduction in the effects table
because this analysis was not reported.Durability
Data on durability of the effect of cladribine and the
comparators are estimates inferred from the mode of
action of the drugs assuming that the drug has
already shown efficacy and that the treatment
interruption occurs for reasons other than efficacy: it
is what physicians generally consider to be an
acceptable interval of time to wait after interrupting a
therapy to switch to another without risking the
appearance of new relapses.Ease of use
Patients with MS who have low adherence to
therapy are at greater risk of relapse than more
adherent patients.23,24 Conversely, patients with MS
who are highly adherent are less likely to have a
relapse or require hospitalization.24e27 Furthermore,
because of the low frequency of exacerbations,
patients have difficulties perceiving the beneficial
impact of being adherent to a drug administered on a
frequent basis. This is a contributing factor to the
“treatment fatigue” phenomenon, where MS patients
become averse to repeated parenteral or oral dosing
over prolonged periods of time, despite the potential
effectiveness of the therapy. Ease of use was therefore
included in the benefit-risk comparison.
Four criteria were considered when ranking the six
drugs for “ease of use”. These were:
(1) Oral versus intravenous administration
(2) The number of doses required (few or many)
(3) Whether monitoring was required during
administration and
(4) Whether co-administration of other drugs was
required.
The six drugs were ranked for overall ease of use
based on these criteria with a score of 1.0 being
assigned to the drug considered to be the most
difficult to use with increments of 0.5 up to the260.e6highest score of 3.5 for the drug perceived to be
easiest to use.
Identification of data for each of the unfavourable
effects
Data on unfavourable effects selected for inclusion
in the model were based upon the important
identified and potential risks associated with
cladribine and the comparator products. Generally
data were captured at the MedDRA System Organ
Class (SOC) level as the terminology across the
different sources varied. For the most part the
comparators data were taken from 2-year studies.
The data sources for the unfavourable effects are
described in the following sections.
Cladribine 3.5 mg/kg
In the integrated analysis of AEs in the placebo-
controlled double-blind cohort, 1458 patients were
exposed to cladribine (all doses) and 745 patients
were exposed to placebo. The placebo controlled,
double-blind cohort without the ONWARD study
was used for the cladribine data (January 2016). This
was compared to the CLARITY clinical study report
(CSR) for validation.
In the Infections and infestations system organ class
(SOC), in the cladribine group AEs were reported for
755/1458, (51.8%) patients (data on file). This value
was entered in the effects table. For comparison, the
incidence rate in the placebo group was 348/745
(46.7%).
Serious adverse events (SAEs) in the Infections and
infestations SOC were reported for 37/1458, (2.5%)
patients in the cladribine group and 12/745 (1.6%) in
the placebo group (data on file). The value of 2.5%
was entered in the effects table for cladribine.
Herpetic infection AEs were reported for 115/1458,
(7.9%) patients in the cladribine group and 24/745
(3.2%) in the placebo group (data on file). The value
of 7.9% has been entered in the effects table for
cladribine.
In the Gastrointestinal disorders SOC, AEs were
reported for 460/1458 (31.6%) patients in the
cladribine group and 233/745 (31.3%) patients in the
placebo group (data on file). The value of 31.6% was
entered in the effects table for gastrointestinal (GI)
effects.
In the Hepatobiliary disorders SOC, AEs were
reported for 22/1458 (1.5%) patients in theVolume 41 Number 2
P. Vermersch et al.cladribine group and 12/745 (1.6%) in the placebo
group (data on file). The value of 1.5% was entered
in the effects table for liver function.
In the Immune system disorders SOC, AEs were
reported for 29/1458 (2.0%) patients, in the
cladribine group and 11/745 (1.5%) patients in the
placebo group (data on file). The value of 2.0% was
entered in the effects table for autoimmune disease.
Bradycardia was reported for 3/1458 (0.2%)
patients in the cladribine group and was not recorded
for any patients in the placebo group (data on file).
There were no events of atrioventricular block in
either treatment group (data on file).
There were no cases of progressive multifocal
leukoencephalopathy (PML) reported in the studies
(data on file).
For the analysis of malignancy, the “All exposed”
cohort was used, comprising all Phase II/III studies
with any formulation of cladribine. It contained the
maximum safety data available and was used to assess
cladribine safety profile over time and in comparison
to placebo. This cohort includes patients from the
ONWARD study who were on background IFN-b
therapy. The All exposed cohort comprised 1976
patients in the cladribine group (all doses) and 802
patients in the placebo group, with 8650 and 2361
patient years at risk, respectively. In this cohort, 32
patients in the cladribine group and 4 patients in the
placebo group had at least one malignant tumor,
giving an incidence per 100 PY of 0.37 and 0.17,
respectively (data on file). The value of 0.37 cases per
100 PY was entered in the effects table.
Grade 4 lymphopenia was infrequent throughout
the clinical program. In CLARITY, Grade 4
lymphopenia occurred in 13 patients (2.9%) treated
with oral cladribine at 5.25 mg/kg and in only 3
patients (0.7%) treated at 3.5 mg/kg (data on file).
The value of 0.7% was entered in the effects table
for lymphopenia.
Natalizumab 300mg
Natalizumab is generally well tolerated but is
associated with a small but confirmed risk of PML,
which prompted the drug's temporary withdrawal
from the US market in February 2005.
Because of the risk of PML, natalizumab is available
in the US only through a restricted program under a
REMS called the TOUCH Prescribing Program.3
More than 450 post-marketing cases of PML,February 2019resulting in more than 100 fatalities, have been
reported with natalizumab monotherapy; survivors of
PML (~80% of MS patients with PML) are left with
varying degrees of disability.
The most important of the unfavourable effects in
the comparison as far as natalizumab is concerned is
therefore PML. A value of 2.1 cases per 1000
patients was included based on the report that as of
February 29, 2012, there were 212 confirmed cases
of PML among 99,571 patients treated with
natalizumab.28
A total of 1617 multiple sclerosis patients in
controlled studies received natalizumab, with a
median duration of exposure of 28 months.3 Of these
1617 patients, 1192 (73.7%) had an infection and 39
(2.4%) had a serious infection.29 These values
(73.7% and 2.4%) are entered in the effects table. It
should be noted that in these trials 839/1135
(73.9%) of patients receiving placebo also had an
infection and 26/1135 (2.3%) had a serious
infection.29
In Study 1 (monotherapy study), which enrolled
patients who had not received any IFN-b or
glatiramer acetate for at least the previous six
months, herpes infection was reported by 8% of
patients.3
For the current analysis of malignancy risk data the
incidence for natalizumab-treated patients was 0.32/
100 patient-years (All exposed) compared to 0.65/
100 patient-years for placebo-treated patients.30
For the remaining unfavourable effects in the
analysis, (ie GI effects, liver function, autoimmune
disease, lymphopenia, AV block, and bradycardia) a
value of zero was entered for natalizumab.
Fingolimod 0.5mg
In multiple sclerosis clinical studies the overall rate
of infections (65.1%) at the 0.5 mg dose was similar
to placebo.31 The 65.1% value was entered in the
effects table.
FREEDOMS II was a double-blind, randomized,
placebo-controlled, Phase III trial that started shortly
after the pivotal Phase III FREEDOMS and
TRANSFORMS studies had started and was part of
the global clinical development program to
investigate fingolimod in multiple sclerosis.
In this study, AEs in the gastrointestinal disorders
SOC were reported by 155/358 (43%) patients in the
fingolimod 0.5 mg group, compared with 143/355260.e7
Clinical Therapeutics(40%) in the placebo group.32 The 43% value was
entered in the effects table.
In clinical trials, elevations 3-fold the upper limit of
normal (ULN) or greater in alanine aminotransferase
(ALT) occurred in 8.0% of patients treated with
fingolimod 0.5 mg compared to 1.9% of placebo
patients.
Elevations 5-fold the ULN occurred in 1.8% of
patients on fingolimod and 0.9% of patients on
placebo.31 In the EPAR, the data from three
completed, double-blind, controlled MS studies and
interim data from two long-term extension studies in
MS patients were pooled into five datasets using
appropriate cut-offs to accommodate differences
between studies in duration of treatment, doses, and
comparators. In one of these datasets (24-month
treatment; N ¼ 1272), 43/425 (10.1%) patients in the
fingolimod 0.5 mg group had an AE of ALT increased
compared with 16/418 (3.8%) patients in the placebo
group and 50/429 (11.7%) in the fingolimod 1.25 mg
group.7The10.1%valuewas entered in the effects table.
In the same dataset (24-month treatment;
N ¼ 1272), 7/425 (1.6%) patients in the fingolimod
0.5 mg group had a serious adverse event (SAE) in
the system organ class (SOC) Infections and
infestations compared with 8/418 (1.9%) patients in
the placebo group and 11/429 (2.6%) in the
fingolimod 1.25 mg group.7 The 1.6% value was
entered in the effects table for serious infections.
In placebo-controlled trials, the rate of herpetic
infections was 9% in patients receiving fingolimod
0.5 mg and 7% in patients receiving placebo.33 The
9% value was entered in the effects table.
For the current analysis of malignancy risk data the
incidence of basal cell carcinoma for fingolimod
0.5 mg-treated patients was 0.4/100 patient-years
across all studies (controlled and extensions).34
Within 4e6 hours after the first dose of fingolimod
0.5 mg, the lymphocyte count decreases to
approximately 75% of baseline in peripheral blood.
With continued daily dosing, the lymphocyte count
continues to decrease over a two-week period,
reaching a minimal count of approximately 500 cells/
mL or approximately 30% of baseline. A total of
18% of patients reached a minimal count below
200 cells/mL (CTC Grade 4) on at least one
occasion.31 Low lymphocyte counts are maintained
with chronic daily dosing. The 18% value was
entered in the effects table.260.e8In multiple sclerosis clinical studies first-degree
atrioventricular block (prolonged PR interval on ECG)
was detected after treatment initiation in 4.7% of
patients on fingolimod 0.5 mg, in 2.8% of patients on
intramuscular IFN-b-1a, and in 1.6% of patients on
placebo. Second-degree atrioventricular block was
detected in less than 0.2% patients on fingolimod
0.5mg. The 4.7%valuewas entered in the effects table.31
In the completed pivotal Phase III MS studies,
bradycardial AV conduction abnormalities were
reported as AEs by 35/854 (4.1%) patients on
fingolimod 0.5 mg and 9/418 (2.2%) patients on
placebo.35 The 4.1% value was entered in the effects
table.
As of August 2015, according to Novartis' Gilenya
Information Center webpage, more than 125,000
patients have been treated with fingolimod and there
are 240,000 patient years of exposure in both clinical
trials and the post-marketing setting. In the Gilenya
risk management plan (RMP) dated 24 February
2015, there had been 11 cases of PML in patients
(with prior history of natalizumab use).35 A further 2
cases of PML have been reported during 2015 giving
13 cases in total. Therefore, a value of 0.104 cases
per 1000 patients was entered into the effects table.
For autoimmune disease, a value of 0% was entered
for fingolimod as this risk is not relevant for this drug.Alemtuzumab 12 mg
The most common adverse events in the
alemtuzumab development program were infusion
reactions, reported in 90% of patients in the Phase
III studies,9,10,36 of which approximately 3% were
regarded as serious. There were no cases of
anaphylaxis and no infusion reactions resulted in
death in the Phase III studies. Infections (eg,
respiratory/urinary tract infection, oral herpes,
sinusitis) were more common in the alemtuzumab
group than in the IFN-b-1a group in the Phase III
studies; most were mild to moderate and none were
life-threatening. By 24 months, approximately 17%
of patients in the alemtuzumab group had thyroid-
associated adverse events and 1% had immune
thrombocytopenia. Alemtuzumab has not been
associated with any cases of PML in studies of
patients with MS (although there have been cases in
patients treated with alemtuzumab for transplant
rejection or for chronic lymphocytic leukemia).9,10,36Volume 41 Number 2
P. Vermersch et al.In light of the potentially serious autoimmune and
other side effects that can occur many months to years
after treatment with alemtuzumab, a strict monitoring
program is in place requiring monthly complete blood
count with differential, urine, and serum creatinine and
quarterly thyroid function testing; moreover, according
to the US and European labels, patients must be
monitored for 48 months following their last infusion.
The AE profile in the dataset including all Phase II/
III active-controlled studies, is presented in Table 35 of
the Lemtrada EPAR.11 Overall the incidence of
infections reported as an AE was 652/919 (70.9%)
for alemtuzumab 12 mg and 264/496 (53.2%) for
IFN-b-1a. The incidence of serious infections was 25/
919 (2.7%) patients for alemtuzumab 12 mg and 5/
496 (1.0%) patients for IFN-b-1a over 2 years of
follow up in the Phase II/III active-controlled studies
(Table 36 of the Lemtrada EPAR).11 The incidence of
herpetic infections was 144/919 (15.7%) patients in
the alemtuzumab 12 mg group and 15/496 (3.0%)
patients in the IFN-b-1a group (Table 66 of the
Lemtrada FDA background package).37
AEs in the gastrointestinal disorders SOC were
reported by 450/919 (49.0%) patients in the
alemtuzumab 12 mg group and by 163/496 (32.9%)
patients in the IFN-b-1a group.11
In the Immune system disorders SOC, AEs were
reported by 53/919 (5.8%) patients in the
alemtuzumab 12 mg group and by 16/496 (3.2%)
patients in the IFN-b-1a group.11 However, a real-
world study of the long-term (mean follow-up of 6.1
years) efficacy and safety of alemtuzumab treatment
in patients with RRMS has recently been reported
and has shown a much higher level of autoimmunity
than was seen in the trials. One hundred patients
were identified with a mean follow-up of 6.1 years
(range 1e13). Forty patients were retreated with at
least one further treatment cycle. Approximately half
(47/100) of the patients included in the study
developed secondary acquired autoimmune disease
(AID), with 35% of patients developing thyroid
AIDs.38 The value of 47% was entered in the effects
table for autoimmune disease.
In total, 22 of 1485 (1.5%) alemtuzumab-treated
patients had a treatment-emergent adverse event of
malignancy, as of 20 April 2013, at which point
5874 person-years of follow-up were available, giving
an incidence per 100 PY of 0.374.37 The value of
0.37 cases per 100 PY was entered in the effects table.February 2019A rapid depletion of circulating T and B
lymphocytes, caused by the anti-CD52 mechanism of
alemtuzumab action, results in nearly all patients in
MS clinical trials experiencing lymphopenia following
treatment. In analyses of worst post-baseline platelet
count by CTC Grade, alemtuzumab-treated patients
had lower frequencies of grade 1 and grade 2
changes in lymphocytes, compared to IFN-b-1a
patients, because the majority of alemtuzumab
patients had grade 3 or grade 4 abnormalities. A
total of 479/919 (52.1%) patients in the
alemtuzumab 12 mg group had a post-baseline
lymphopenia of CTC Grade 4, compared to 1/492
(0.2%) patients in the IFN-b-1a group (Lemtrada
FDA background package, Table 84).37
In controlled trials, in the alemtuzumab 12 mg
group, one patient each had SAEs of bradycardia,
sinus bradycardia and sick sinus syndrome (Lemtrada
FDA background package, Table 21).37 Therefore, 3/
919 (0.3%) of patients in the alemtuzumab 12 mg
group had a bradycardia (compared to none in the
IFN-b-1a group). A value of 0.3% was included in
the effects table for bradycardia.
There were no AEs of elevated liver enzymes or AV
block and no cases of PML in patients treated with
alemtuzumab 12 mg and so values of zero were
entered in the effects table for these risks.
Dimethyl fumarate
The most commonly reported side effects in clinical
trials were flushing and GI side effects. The incidence of
GI events was higher early in the course of treatment
(primarily in the first month) and usually decreased
over time in patients treated with dimethyl fumarate
compared with placebo. An increased incidence of
elevations of hepatic transaminases in patients treated
with dimethyl fumarate was seen primarily during the
first 6 months of treatment, and most patients with
elevations had levels <3 × ULN. A transient increase
in mean eosinophil counts was seen during the first
two months of therapy. The rate of serious adverse
events in the Phase III trials was lower than that of
placebo, and there were no opportunistic infections
or differences between treatment groups with regard
to malignancies.14
In November 2014, the FDA released a safety
warning in the wake of a fatal case of PML that
occurred in an MS patient who was being treated
with dimethyl fumarate. In December 2014, the US260.e9
Clinical Therapeuticsand European labels for dimethyl fumarate were
updated to include information about the risk of
PML, outlining more frequent complete blood count
(CBC) monitoring (every 6 to 12 months, as opposed
to annually), and establish a lymphocyte
concentration threshold at which to consider
interruption of treatment with the drug (0.5 × 109/
L).14,39
Apart from the CBC requirement, no additional
monitoring is required or recommended in the US
label, but in the European label, liver and kidney
function tests are recommended prior to starting
treatment, after 3 and 6 months of treatment, and
annually thereafter, as well as at physicians' discretion.
The AE profile in the dataset including all placebo-
controlled studies, is presented in Section 2.6.2 of the
Tecfidera EPAR.16 Overall the incidence of infections
reported as an AE was 60% for dimethyl fumarate
240 mg bid (463 patients) and 56% for placebo (469
patients).
The incidence of serious infections was similar (2%
vs 2%) in patients treated with dimethyl fumarate
240 mg bid or placebo, respectively (Section 5.3 of
the Tecfidera US PI).14
AEs in the gastrointestinal disorders SOC were
reported at an increased incidence with dimethyl
fumarate 120 mg bid compared with placebo in both
placebo-controlled studies, Study 109MS301
(DEFINE): 44% vs 36% on placebo and Study
109MS302 (CONFIRM): 36% vs 26% on placebo.16
The higher value (44%) has been entered into the
effects table.
Elevations of liver transaminases were reported as
AEs at a slightly higher incidence with dimethyl
fumarate 120 mg bid compared to placebo: AEs of
increased alanine transaminase (ALT) were reported
for 6% of patients in the dimethyl fumarate 120 mg
bid group compared with 5% in the placebo group.16
Including patients with longer term treatment, the
incidence of malignancies overall among dimethyl
fumarate-treated patients was 0.375 per 100 patient
years (95% CI 0.219, 0.601).40
In the placebo-controlled studies, most patients
(>98%) had normal lymphocyte values prior to
initiating treatment. Upon treatment with dimethyl
fumarate, mean lymphocyte counts decreased over
the first year with a subsequent plateau. On average,
lymphocyte counts decreased by approximately 30%
of baseline value. Lymphocyte counts <0.5 × 109/L260.e10were observed in <1% of patients treated with
placebo and 6% of patients treated with dimethyl
fumarate. A lymphocyte count <0.2 × 109/L (CTC
Grade 4) was observed in 1 patient treated with
dimethyl fumarate and in no patients treated with
placebo.39 It was not clear from the SmPC if the
patient was in the bid (769 patients) or tid (771
patients) group but the incidence was calculated as
0.13% and this value has been entered in the effects
table.
To November 2015 there have been four reported
cases of PML according to the Biogen website. An
incidence of 0.029 cases per 1000 patients was
calculated using the denominator of 135,000 patients
treated to March 2013 with dimethyl fumarate (again
taken from the Biogen website). This value is
therefore an overestimate as more patients will have
received dimethyl fumarate since 2013.
For the remaining unfavourable effects in the
analysis, (autoimmune disease, AV block,
bradycardia, and herpetic infections) a value of zero
was entered for dimethyl fumarate as they are not an
issue for this drug.
Teriflunomide 14 mg
In the clinical studies the most common adverse
reactions were headache, an increase in ALT,
diarrhea, alopecia, and nausea. There were no deaths
or serious opportunistic infections in the Phase III
trials, and no data have confirmed an increased risk
of malignancy or infections.18
Teriflunomide's US label carries a black-box
warning of hepatotoxicity based on preclinical
studies, and according to teriflunomide's prescribing
information, initial liver function and hematological
monitoring is required. Transaminase and bilirubin
levels must be obtained prior to initiation and ALT
levels must be monitored at least monthly for six
months; recent blood count and a tuberculin skin test
should be obtained before initiation and patients
should be monitored for signs of infection.
Teriflunomide has been shown to be teratogenic in
animal tests.
Treatment during pregnancy is contraindicated and
treatment is not recommended if a patient is planning a
pregnancy. Teriflunomide has a long elimination half-
life and, in the event of pregnancy or toxicity, an
accelerated elimination procedure using
cholestyramine or activated charcoal for 11 days (asVolume 41 Number 2
P. Vermersch et al.described in the prescribing information) may be
required.18
The AE profile in the dataset including all placebo-
controlled studies, is presented in Table 33 of the
Aubagio EPAR.21 Overall the incidence of infections
reported as an AE was 256/415 (61.7%) for
teriflunomide 14 mg and 242/421 (57.5%) for
placebo. SAEs in the Infections and infestations SOC
were reported by 2.2% of patients in the
teriflunomide 14 mg group and 2.1% of patients in
the placebo group.21
AEs in the gastrointestinal disorders SOC were
reported by 45.3% of patients in the teriflunomide
14 mg group and 34.4% of patients in the placebo
group.21
AEs of increased alanine transaminase (ALT) were
reported for 150/1002 (15.0%) patients in the
teriflunomide 14 mg group compared with 89/997
(8.9%) in the placebo group (Hepatic Effects
Table 1c in the Aubagio RMP, Module SVII).41
The number of patients with malignant and benign
tumor AEs were 0.3% on teriflunomide 14 mg and
0.5% on placebo (Table 11 in the Aubagio RMP).41
Exposure-adjusted incidence rate (EAIR) per 100
patient-years was 0.2 in the teriflunomide 14 mg
group compared with 0.3 in the placebo group
(Table 11 in the Aubagio RMP, Module SVII).41
The number of patients with serious opportunistic
infections, including PML, is summarized in Table 9a
in the Aubagio RMP, Module SVII.41 No case of
PML was reported in the whole teriflunomide
program (Aubagio RMP, Module SVII).41 The
number of patients who had an AE of the PT
“Herpes virus infection” was 5/1002 (0.5%) in the
teriflunomide 14 mg group (Table 9a in the Aubagio
RMP, Module SVII)41 and this value (0.5%) was
entered into the effects table. This is an underestimate
of the incidence of herpetic infections as other PTs in
the table were not taken into account (eg, oral herpes
22/1002 [2.2%], Herpes simplex 9/1002 [0.9%] and
Herpes zoster 9/1002 [0.9%]). However, it was not
possible to determine which of these events occurred
in the same patients. The value entered in the effects
table favours teriflunomide.
For the remaining unfavourable effects in the
analysis, (autoimmune disease, lymphopenia, AV




Two approaches to sensitivity analysis of the model
have been considered. The first looks at varying the
weighting applied to the individual favourable and
unfavourable effects to see if applying different
weights would substantially change the overall result.
The second changes input data for some drugs on
key criteria to see the effects on the overall result.
The experts were most unsure of the weights they
had assessed when comparing the biggest swing
weights for each of the favourable and unfavourable
effects, EDSS 6 months compared to PML. The
relative weights between those two criteria was
judged to be about equal, so given weights of 100-
100. As lower-level weights had already been
compared, Hiview3 then normalised all weights so
their sum equalled 100, preserving the ratios of all
the weights. Any sum of normalised weights is
termed a cumulative weight.
Sensitivity analyses then proceeded by changing the
sum of the normalised weights under the unfavourable
effects node for both models. For the RRMS model,
shown in Supplementary Figure 1, the intersection of
the vertical line (located at the cumulative weight of the
unfavourable effects, 50.7) with the top-most sloping
line defines the most preferred option. In the RRMS
model, changing the weight on the unfavourable effects
node from its value of 50.7 to any value between 0 and
100 showed that dimethyl fumarate was the most
preferred drug over a range from about 49 to 96, with
changes in the most preferred drug indicated by
transitions to green shading. Less than 39 and
alemtuzumab is most preferred; more than 96 and
teriflunomide is most preferred. Interestingly, at the
precise weight of 40, dimethyl fumarate, cladribine and
alemtuzumab are nearly equal in preference. Over a
range from 40 to 49 cladribine is most preferred, while
beyond 49 cladribine is in second position compared to
dimethyl fumarate.
As for changing weights on individual criteria,
cladribine becomes most preferred only with
increases of the weight on any of Ease of Use,
Durability or Infections (not shown).260.e11
Clinical TherapeuticsSupplementary Figure 1. Sensitivity analysis for the
unfavourable effects in the RRMS model
The sensitivity analysis for the HDA model
showed that cladribine is most preferred over the
19 to 87 range of weights for the unfavourable260.e12effects (Supplementary Figure 2). At a weight less
than 19, alemtuzumab is most preferred; above 87,
dimethyl fumarate is most preferred until the
weight reaches about 96, when teriflunomide
becomes best.Volume 41 Number 2
P. Vermersch et al.Changing weights for individual criteria showed
that cladribine remained most preferred for any
weight from 0 to 100 on 6 months confirmed EDSS
progression, Ease of Use, and Any Infections. For all
other criteria, an increase of more than 15 points is
required for another drug to become most preferred.
Supplementary Figure 2. Sensitivity analysis for the
unfavourable effects in HDA model.Sensitivity analysis of input data for the favourable
effects
The second approach changes input data in the Effects
Table. For the favourable effects, more optimistic effects
for the other treatment options were considered (except
for alemtuzumab). For the unfavourable effects, more
pessimistic effects for clabribine were assumed.
Sensitivity analysis for the favourable effects
focusses on reduction in the 3-months and 6-months
EDSS progression. The changes in input data of
EDSS progression assigned to DMDs in this
sensitivity analysis (see below) are considered to be
within the realm of clinical possibilities.
For alemtuzumab, in an active comparator (IFN-b-
1a) Phase III trial in treatment-experienced patients
with relapsing-remitting multiple sclerosis (RRMS),
there was a 42% reduction in 6-month confirmed
EDSS progression, relative to IFN-b-1a.9 There are
no placebo-controlled studies of alemtuzumab and so
the 42% value was arbitrarily increased by 20%, on
the assumption that the effect would have been
greater relative to placebo, to give a value of 62%
which was entered in the effects table. The same
value was used in the effects table for the input data
of the 3-month confirmed EDSS progression, because
this analysis was not reported. This was a
conservative approach. For the sensitivity analysis an
arbitrary value of 52% was used for both the 3-
month and 6-month confirmed EDSS progression in
the RRMS population.
For teriflunomide, a data value of 31% was used for
3-month confirmed EDSS progression in the benefit-
risk analysis in the RRMS population, based on the
result in one of the placebo controlled pivotal studies
(TOWER) (the corresponding result in the other
pivotal study [TEMSO] was 29.8%). The input dataFebruary 2019value used for the 6-month confirmed EDSS
progression was 24%, based on the integrated
analysis of the TOWER and TEMSO studies. For the
sensitivity analysis, an arbitrary value of 62% was
used for both the 3-month and 6-month confirmed
EDSS progression.Sensitivity analysis for the high disease activity
(HDA) subpopulation
For the high disease activity (HDA) subpopulation,
the following amendments were made to the input
data for the sensitivity analysis:
For alemtuzumab the input data for 3-month and 6-
month confirmed EDSS progression was increased to
82% for both (to match cladribine). Similarly, the
input data for 3-month and 6-month confirmed EDSS
progression for natalizumab was increased to 82%
for both (to match cladribine). For dimethyl fumarate
the input data for 3-month and 6-month confirmed
EDSS progression was doubled from 21% in the
main analysis to 42% in the sensitivity analysis. For
fingolimod, the input data for 3-month and 6-month
confirmed EDSS progression was increased from
33% to 42% in the sensitivity analysis.Sensitivity analysis of input data for the unfavourable
effects
The unfavourable effects of malignancy,
lymphopenia (grade 4) and PML most relevant for
cladribine assessment were chosen for the sensitivity
analyses. For the sensitivity analysis of these
unfavourable effects, the cladribine values for
lymphopenia (Grade 4) and malignancy were changed
to the most negative value among the other treatment
options (52.1% for lymphopenia [Grade 4] and 0.4
new cases per 100 patient years for malignancy).
There were no cases of PML reported in the
cladribine studies in multiple sclerosis. The risk of
PML for cladribine is currently unknown. The
cladribine value for PML was changed to be the
same value as fingolimod (0.104 cases per 1000
patients). A second sensitivity analysis was done with
cladribine assigned a value for PML that was double
that used for fingolimod in the main analysis (0.208
cases per 1000 patients).260.e13
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The changes to the data in the effects table for input
into the model are shown in Supplementary Table 1.
Input data that were changed in this sensitivity
analysis are shown in bold italicized font in the table.
The overall weighted preference values from the
original analysis showed that dimethyl fumarate and
cladribine were most preferred for the RRMS model,
and cladribine was most preferred for the HDA model.
EDSS is a relevant measure included in most major
DMD clinical trials conducted in the past four
decades. Slowing disability progression is the ultimate
goal for DMD therapies in MS and for this reason,
this measure was chosen for the sensitivity analysis
for the favourable effects.
The sensitivity analysis for the favourable effects
included large favourable changes to values assigned
to DMDs other than cladribine. Despite these
favourable hypothetical values assigned to
comparators, cladribine retained its place in terms of
benefit-risk, as the most preferred agent for HDA and
its second position (after dimethyl fumarate) for
RRMS.
The unfavourable effects ofmalignancy, lymphopenia
(Grade 4) and PML most relevant for cladribine260.e14assessment were chosen for the sensitivity analyses.
Unfavourable hypothetical values were assigned to
cladribine for these effects. For the RRMS model, when
the % of patients experiencing lymphopenia (Grade 4)
for cladribine was changed from 0.7% to 52.1%, the
overall weighting for cladribine was reduced from 62 to
56 (ie, similar to natalizumab [56] and alemtuzumab
[55] and lower than dimethyl fumarate [63]. This was
the only sensitivity analysis in which the relative
preference for cladribine compared to another DMD
was not maintained
For the HDA model, cladribine remained the most
preferred option in all of the sensitivity analyses.
Even when the % of patients experiencing
lymphopenia (Grade 4) for cladribine was changed
from 0.7% to 52.1%, the resulting overall weighting
for cladribine (70) was still the highest of the six
drugs being compared.
In conclusion, these sensitivity analyses indicate that
cladribine has a robust benefit-risk balance compared
to other marketed agents for MS (highest in HDA
patients and second highest in RRMS patients) and
are consistent with the original analyses performed
with values derived from the clinical trials of these
agents.Volume 41 Number 2
Supplementary Table 1. Input data for the RRMS Population and the HDA Subset (data shown in parentheses) in the sensitivity analysis
(values changed shown in bold italics)




Relapse rate Relative reduction,
compared to the control,
in annualized relapse rate
at 2 years
% 58 (68) 68 (81) 54 (63) 53 (60) 75 (71) 36 (19)
T2 lesions Relative reduction in mean
number of active T2
lesions per patient per
scan over 2 years
% 73 83 74 85 87 (92) 53
T1 Gd+ lesions Relative reduction in mean
number of T1 Gd+ lesions
per patient per scan over 2
years
% 86 92 82 94 92 (97) 80
EDSS 3 months Relative reduction in time to
3-month
confirmed EDSS
progression over 2 years
% 33 (72) 42 (82) 30 (42) 38 (42) 52(82) 62 (35)
EDSS 6 months Relative reduction in the time
to 6-month
confirmed EDSS
progression over 2 years
% 47 (82) 54 (82) 37 (42) 23 (42) 52 (82) 62 (35)
Ease of use Ranking based on 4 sub-
criteria*
1e3.5 3.5 1.5 2.0 2.5 1.0 3.0
Durability Number of months of
remaining efficacy after
stopping the drug
Months 12 2 1 1 12 1
Unfavourable effects
AR infections Percentage of patients with
any infections
% 51.8 73.7 65.1 60.0 70.9 61.7
AR GI effects Percentage of patients with
any GI disorder
% 31.6 0.0 43.0 44.0 49.0 45.3











Supplementary Table 1. (Continued)
Criteria Description Metric Cladribine Natalizumab Fingolimod Dimethyl
fumarate
Alemtuzumab Teriflunomide
Liver functions Percentage of patients
experiencing elevated
liver enzymes
% 1.5 0.0 10.1 6.0 0.0 15.0
Malignancy Number of new cases per
100 patient-years
No/100 0.4 0.320 0.400 0.375 0.370 0.200
Autoimmune
disease
Percentage of patients with
any autoimmune
disease
% 2.0 0.0 0.0 0.0 47.0 0.0
Lymphopenia Percentage of patients
experiencing lymphopenia
Grade 4
% 52.1 0.0 18.0 0.13 52.1 0.0
AV block Percentage of patients with
first degree AV
block
% 0.0 0.0 4.7 0.0 0.0 0.0
Bradycardia Percentage of patients with
bradycardia
% 0.2 0.0 4.1 0.0 0.3 0.0
Serious
infections
Percentage of patients with
any serious
infection





% 7.9 8.0 9.0 0.0 15.7 0.5
PML Number of cases of PML per
1000 patients
No/1000 0.104/0.208 2.100 0.104 0.029 0.000 0.000
Note. This table shows changes input data used in sensitivity analyses of the effects of different input data on the overall results. For the favourable effects, more
optimistic effects for the other treatment options are considered. For the unfavourable effects, more pessimistic effects for cladribine were assumed. The values
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